Clopidogrel Tablets Recalled, May Contain Simvastatin Clopidogrel Tablets Recalled, May Contain Simvastatin

International Laboratories issued the recall because the tablets, labeled as clopidogrel 75 mg, may contain the cholesterol-lowering drug simvastatin, an FDA safety alert notes.News Alerts
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

Related Links:

ABSTRACTSeveral epidemiological studies have reported a relationship between statin treatment and increased bone mineral density (BMD) and reduced fracture risk, but the mechanism underlying the purported relationship is unclear. We used Mendelian randomization (MR) to assess whether this relationship is explained by a specific effect in response to statin use or by a general effect of lipid lowering. We utilized 400 single ‐nucleotide polymorphisms (SNPs) robustly associated with plasma lipid levels as exposure. The outcome results were obtained from a heel estimated BMD (eBMD) genomewide association study (GWAS) from t...
Source: Journal of Bone and Mineral Research - Category: Orthopaedics Authors: Tags: Original Article Source Type: research
To explore the effects of statin therapy with the abdominal aortic aneurysm (AAA) growth rate and mortality.
Source: Annals of Vascular Surgery - Category: Surgery Authors: Tags: General Review Source Type: research
This study aimed to examine whether sappanwood ethyl acetate extract (SEAE) alleviates experimental atherosclerosis in rats through FGF21/SREBP-2 signaling. Rats were randomized to six groups (n=10/group): blank control, model, simvastatin (positive control, 4.2 mg/kg/d), and SEAE high-, medium-, and low-dose (2.30, 1.15, and 0.575 g/kg/d, respectively). The high-fat- and vitamin D3-induced rodent model of atherosclerosis was created (except in the blank control group). Aorta and liver underwent histopathologic examination. SREPB-2 and FGF21 expression levels were examined by real-time RT-PCR and western blot. Compared wit...
Source: International Journal of Clinical and Experimental Pathology - Category: Pathology Authors: Tags: Int J Clin Exp Pathol Source Type: research
Clinical Liver Disease, Volume 15, Issue 2, Page 69-70, February 2020.
Source: Clinical Liver Disease - Category: Gastroenterology Authors: Tags: Review Source Type: research
Hwang Statins such as simvastatin have many side effects, including muscle damage, which is known to be the most frequent undesirable side effect. Lysophosphatidic acid (LPA), a kind of biolipid, has diverse cellular activities, including cell proliferation, survival, and migration. However, whether LPA affects statin-linked muscle damage has not been reported yet. In the present study, to determine whether LPA might exert potential protective effect on statin-induced myocyotoxicity, the effect of LPA on cytotoxicity in rat L6 myoblasts exposed to simvastatin was explored. Viability and apoptosis of rat L6 myoblasts we...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
In conclusion, berberine-induced nuclear translocation of FXR and LXRα could activate OATP1B1 promoter, resulting in enhanced expression of OATP1B1 and increased uptake of rosuvastatin.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Risk for heart failure hospital visit declined with statins for women receiving anthracyclines, trastuzumab
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Cardiology, Gynecology, Oncology, Pharmacy, Conference News, Source Type: news
Condition:   Diabetes Intervention:   Sponsor:   University Hospital, Montpellier Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Hermans MP, Ahn SA, Rousseau MF Abstract Background: New recommendations call for lowering LDL-C 
Source: Acta Cardiologica - Category: Cardiology Tags: Acta Cardiol Source Type: research
Abstract Diabetes mellitus (DM) is one of the most common diseases in the world. Among its effects are an increase in the risk of cognitive impairment, including Alzheimer's disease, and blood-brain barrier (BBB) dysfunction. DM is characterized by high blood glucose levels that are caused by either lack of insulin (Type I) or resistance to the actions of insulin (Type II). The phenotypes of these two types are dramatically different, with Type I animals being thin, with low levels of leptin as well as insulin, whereas Type II animals are often obese with high levels of both leptin and insulin. The best characteri...
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
More News: Cardiology | Cholesterol | Clopidogrel | Health | Heart | Plavix | Simvastatin | Statin Therapy | Zocor